Efficacy of d-penicillamine, a sequestering acetaldehyde agent, in the prevention of alcohol relapse-like drinking in rats

Psychopharmacology

Volumn 228, Issue 4, 2013, Pages 563-575

  Orrico, Alejandro ^a   Hipólito, Lucía ^b   Sánchez Catalán, María José ^c   Martí Prats, Lucía ^a   Zornoza, Teodoro ^a   Granero, Luis ^a   Polache, Ana ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b NewYork Presbyterian Hospital   (United States)

^c Hopitaux Universitaires de Strasbourg   (France)

Author keywords

Acetaldehyde sequestering agents; Alcohol deprivation effect; d Penicillamine; Ethanol relapse prevention

Indexed keywords

ACETALDEHYDE; PENICILLAMINE;

ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INFUSION; FEEDING BEHAVIOR; MALE; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; RAT; RELAPSE; TREATMENT DURATION; VENTRAL TEGMENTUM;

ACETALDEHYDE; ALCOHOL DRINKING; ALCOHOLISM; ANIMALS; BRAIN; CHELATING AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOL; INFUSION PUMPS, IMPLANTABLE; MALE; OSMOTIC PRESSURE; PENICILLAMINE; RATS; RATS, WISTAR; RECURRENCE; TIME FACTORS; TISSUE DISTRIBUTION; VENTRAL TEGMENTAL AREA;

EID: 84881218221     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3065-1     Document Type: Article

References (53)

1. Addolorato G, Leggio L, Hopf FW, Diana M, Bonci A (2012) Novel therapeutic strategies for alcohol and drug addiction: focus on GABA, ion channels and transcranial magnetic stimulation. Neuropsychopharmacology 37:163-177. doi: 10.1038/npp.2011.216
2. Andlin-Sobocki P, Rehm J (2005) Cost of addiction in Europe. Eur J Neurol 12(Suppl 1):28-33. doi: 10.1111/j.1468-1331.2005.01194.x
3. 2 system. Biochem Pharmacol 44:93-98
4. Bergstrom RF, Kay RD, Wagner JG (1981) The pharmacokinetics of penicillamine in a female mongrel dog. J Pharmacokinet Biopharm 9:603-621
5. Brager A, Prosser RA, Glass JD (2011) Acamprosate-responsive brain sites for suppression of ethanol intake and preference. Am J Physiol Regul Integr Comp Physiol 301:R1032-43. doi: 10.1152/ajpregu.00179.2011
6. Burish TG, Maisto SA, Cooper AM, Sobell MB (1981) Effects of voluntary short-term abstinence from alcohol on subsequent drinking patterns of college students. J Stud Alcohol 42:1013-1020
7. Cederbaum AI, Rubin E (1976) Mechanism of the protective action of cysteine and penicillamine against acetaldehyde-induced mitochondrial injury. Biochem Pharmacol 25:2179-2185
8. Correa M, Salamone JD, Segovia KN, Pardo M, Longoni R, Spina L, Peana AT, Vinci S, Acquas E (2012) Piecing together the puzzle of acetaldehyde as a neuroactive agent. Neurosci Biobehav Rev 36:404-430. doi: 10.1016/j.neubiorev. 2011.07.009
9. Edwards S, Kenna GA, Swift RM, Leggio L (2011) Current and promising pharmacotherapies, and novel research target areas in the treatment of alcohol dependence: a review. Curr Pharm Des 17:1323-1332
10. Enrico P, Sirca D, Mereu M, Peana AT, Lintas A, Golosio A, Diana M (2009) Acetaldehyde sequestering prevents ethanol-induced stimulation of mesolimbic dopamine transmission. Drug Alcohol Depend 100:265-271. doi: 10.1016/j.drugalcdep.2008.10.010
11. Foddai M, Dosia G, Spiga S, Diana M (2004) Acetaldehyde increases dopaminergic neuronal activity in the VTA. Neuropsychopharmacology 29:530-536. doi: 10.1038/sj.npp.1300326
12. Font L, Miquel M, Aragon CM (2005) Prevention of ethanol-induced behavioral stimulation by D-penicillamine: a sequestration agent for acetaldehyde. Alcohol Clin Exp Res 29:1156-1164
13. Font L, Aragon CM, Miquel M (2006a) Voluntary ethanol consumption decreases after the inactivation of central acetaldehyde by d-penicillamine. Behav Brain Res 171:78-86. doi: 10.1016/j.bbr.2006.03.020
14. Font L, Aragon CM, Miquel M (2006b) Ethanol-induced conditioned place preference, but not aversion, is blocked by treatment with D-penicillamine, an inactivation agent for acetaldehyde. Psychopharmacology (Berl) 184:56-64. doi: 10.1007/s00213-005-0224-z
15. Granero L, Gimeno MJ, Torres-Molina F, Chesa-Jimenez J, Peris JE (1994) Studies on the renal excretion mechanisms of cefadroxil. Drug Metab Dispos 22:447-450
16. Heilig M, Goldman D, Berrettini W, O'Brien CP (2011) Pharmacogenetic approaches to the treatment of alcohol addiction. Nat Rev Neurosci 12:670-684. doi: 10.1038/nrn3110
17. Heyser CJ, Schulteis G, Koob GF (1997) Increased ethanol self-administration after a period of imposed ethanol deprivation in rats trained in a limited access paradigm. Alcohol Clin Exp Res 21:784-791
18. Hipolito L, Sanchez MJ, Polache A, Granero L (2007) Brain metabolism of ethanol and alcoholism: an update. Curr Drug Metab 8:716-727
19. Holter SM, Spanagel R (1999) Effects of opiate antagonist treatment on the alcohol deprivation effect in long-term ethanol-experienced rats. Psychopharmacology (Berl) 145:360-369
20. Kera Y, Kiriyama T, Komura S (1985) Conjugation of acetaldehyde with cysteinylglycine, the first metabolite in glutathione breakdown by gamma-glutamyltranspeptidase. Agents Actions 17:48-52
21. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE (2005) Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:617-627. doi: 10.1001/archpsyc.62.6.617
22. Kornet M, Goosen C, Van Ree JM (1991) Effect of naltrexone on alcohol consumption during chronic alcohol drinking and after a period of imposed abstinence in free-choice drinking rhesus monkeys. Psychopharmacology (Berl) 104:367-376
23. Kranzler HR, Van Kirk J (2001) Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 25:1335-1341
24. Kreuzig F, Frank J (1981) Rapid automated determination of D-penicillamine in plasma and urine by ion-exchange high-performance liquid chromatography with electrochemical detection using a gold electrode. J Chromatogr 218:615-620
25. Leggio L, Cardone S, Ferrulli A, Kenna GA, Diana M, Swift RM, Addolorato G (2010) Turning the clock ahead: potential preclinical and clinical neuropharmacological targets for alcohol dependence. Curr Pharm Des 16:2159-2118
26. March SM, Abate P, Spear NE, Molina JC (2012) The role of acetaldehyde in ethanol reinforcement assessed by Pavlovian conditioning in newborn rats. Psychopharmacology (Berl). doi: 10.1007/s00213-012-2920-9
27. Marti-Prats L, Sanchez-Catalan MJ, Hipolito L, Orrico A, Zornoza T, Polache A, Granero L (2010) Systemic administration of D-penicillamine prevents the locomotor activation after intra-VTA ethanol administration in rats. Neurosci Lett 483:143-147. doi: 10.1016/j.neulet.2010.07.081
28. McIntosh J, O'Brien T, McKeganey N (2008) Drug driving and the management of risk: the perspectives and practices of a sample of problem drug users. Int J Drug Policy 19:248-254. doi: 10.1016/j.drugpo.2006.12.003
29. Melis M, Enrico P, Peana AT, Diana M (2007) Acetaldehyde mediates alcohol activation of the mesolimbic dopamine system. Eur J Neurosci 26:2824-2833. doi: 10.1111/j.1460-9568.2007.05887.x
30. Nagasawa HT, Goon DJ, DeMaster EG (1978) 2,5,5-Trimethylthiazolidine-4- carboxylic acid, a D(-)-penicillamine-directed pseudometabolite of ethanol. Detoxication mechanism for acetaldehyde. J Med Chem 21:1274-1279
31. Nagasawa HT, Elberling JA, DeMaster EG (1980) Structural requirements for the sequestration of metabolically generated acetaldehyde. J Med Chem 23:140-143
32. Paxinos G, Watson C (2007) The rat brain in stereotaxic coordinates, 6th edn. Academic, San Diego
33. Peana AT, Enrico P, Assaretti AR, Pulighe E, Muggironi G, Nieddu M, Piga A, Lintas A, Diana M (2008) Key role of ethanol-derived acetaldehyde in the motivational properties induced by intragastric ethanol: a conditioned place preference study in the rat. Alcohol Clin Exp Res 32:249-258. doi: 10.1111/j.1530-0277.2007.00574.x
34. Peana AT, Assaretti AR, Muggironi G, Enrico P, Diana M (2009) Reduction of ethanol-derived acetaldehyde induced motivational properties by L-cysteine. Alcohol Clin Exp Res 33:43-48. doi: 10.1111/j.1530-0277.2008.00809.x
35. Peana AT, Muggironi G, Calvisi G, Enrico P, Mereu M, Nieddu M, Boatto G, Diana M (2010) l-Cysteine reduces oral ethanol self-administration and reinstatement of ethanol-drinking behavior in rats. Pharmacol Biochem Behav 94:431-437. doi: 10.1016/j.pbb.2009.10.005
36. Peana AT, Muggironi G, Fois GR, Zinellu M, Sirca D, Diana M (2012) Effect of l-cysteine on acetaldehyde self-administration. Alcohol. doi: 10.1016/j.alcohol.2011.10.004
37. Rosner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M (2010a) Acamprosate for alcohol dependence. Cochrane Database Syst Rev (9):CD004332. doi: 10.1002/14651858.CD004332.pub2
38. Rosner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M (2010b) Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev (12):CD001867. doi: 10.1002/14651858.CD001867.pub2.
39. Salaspuro VJ, Hietala JM, Marvola ML, Salaspuro MP (2006) Eliminating carcinogenic acetaldehyde by cysteine from saliva during smoking. Cancer Epidemiol Biomarkers Prev 15:146-149. doi: 10.1158/1055-9965.EPI-05-0248
40. Salimov RM, Salimova NB (1993) The alcohol-deprivation effect in hybrid mice. Drug Alcohol Depend 32:187-191
41. Sanchez-Catalan MJ, Hipolito L, Guerri C, Granero L, Polache A (2008) Distribution and differential induction of CYP2E1 by ethanol and acetone in the mesocorticolimbic system of rat. Alcohol Alcohol 43:401-407. doi: 10.1093/alcalc/agn012
42. Sanchis C, Aragon CM (2007) What we drink when we drink? The role of the acetaldehyde in the alcohol consumption. Adicciones 19:5-11
43. Serrano E, Pozo OJ, Beltran J, Hernandez F, Font L, Miquel M, Aragon CM (2007) Liquid chromatography/tandem mass spectrometry determination of (4S,2RS)-2,5,5-trimethylthiazolidine-4-carboxylic acid, a stable adduct formed between D-(-)-penicillamine and acetaldehyde (main biological metabolite of ethanol), in plasma, liver and brain rat tissues. Rapid Commun Mass Spectrom 21:1221-1229. doi: 10.1002/rcm.2951
44. Shen XY, Orson FM, Kosten TR (2012) Vaccines against drug abuse. Clin Pharmacol Ther 91:60-70. doi: 10.1038/clpt.2011.281
45. Sirca D, Enrico P, Mereu M, Peana AT, Diana M (2011) L-cysteine prevents ethanol-induced stimulation of mesolimbic dopamine transmission. Alcohol Clin Exp Res 35:862-869. doi: 10.1111/j.1530-0277.2010.01416.x
46. Spanagel R (2009) Alcoholism: a systems approach from molecular physiology to addictive behavior. Physiol Rev 89:649-705. doi: 10.1152/physrev.00013.2008
47. Spanagel R, Holter SM (1999) Long-term alcohol self-administration with repeated alcohol deprivation phases: an animal model of alcoholism? Alcohol Alcohol 34:231-243
48. Spanagel R, Kiefer F (2008) Drugs for relapse prevention of alcoholism: ten years of progress. Trends Pharmacol Sci 29:109-115. doi: 10.1016/j.tips.2007.12.005
49. Spanagel R, Vengeliene V (2012) New pharmacological treatment strategies for relapse prevention. Curr Top Behav Neurosci. doi: 10.1007/7854-2012-205
50. Spanagel R, Zieglgansberger W (1997) Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol Sci 18:54-59
51. Vengeliene V, Bachteler D, Danysz W, Spanagel R (2005) The role of the NMDA receptor in alcohol relapse: a pharmacological mapping study using the alcohol deprivation effect. Neuropharmacology 48:822-829. doi: 10.1016/j.neuropharm.2005.01.002
52. Vengeliene V, Heidbreder CA, Spanagel R (2007) The effects of lamotrigine on alcohol seeking and relapse. Neuropharmacology 53:951-957. doi: 10.1016/j.neuropharm.2007.09.006
53. Zimatkin SM, Pronko SP, Vasiliou V, Gonzalez FJ, Deitrich RA (2006) Enzymatic mechanisms of ethanol oxidation in the brain. Alcohol Clin Exp Res 30:1500-1505. doi: 10.1111/j.1530-0277.2006.00181.x